← Back to Calendar
Live Company Data
NMS
Updated
just now
· Data: FMP
Current Price
$148.63
+304.33%
+$111.87 today
Day: $145.52 – $151.13
Market Cap
N/A
Shares out: 208.74M
Float: 178.73M
52-Week Range
Current price is at 94% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) — oral RAS(ON) multi-selective inhibitor
Key Notes
Phase 3 RASolute 302 trial POSITIVE topline results announced April 13, 2026. Daraxonrasib (oral, once-daily RAS(ON) multi-selective inhibitor targeting KRAS/NRAS G12D/G12V/G12R) vs standard IV chemotherapy in previously treated metastatic PDAC. OS: 13.2 months (daraxonrasib) vs 6.7 months (chemo) — HR 0.40, ~60% reduction in death risk; statistically significant (p<0.0001) at first interim analysis. PFS also met. No new safety signals. First oral RAS-targeting agent to demonstrate OS benefit in Phase 3. RVMD +41% on April 13 to all-time high $136; company raised $750M concurrent equity offering. NDA filing planned Q2 2026 under FDA Commissioner's National Priority Voucher (CNPV) program; full data at ASCO 2026. Also running: RASolute 303 (1L PDAC, first patient April 2) and RASolve 301 (NSCLC). Note: RVMD market cap ~$20B+ post-announcement — above $7B focus threshold but included as major 2026 biotech catalyst.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.